Section 5 of 6
Economic information and modeling report
30 evidence topics · 19 sources
Modeling overview
Summary
- Model structure (NICE TA1199, nirogacestat): a semi-Markov model comparing nirogacestat with best supportive care, to which the EAG added chemotherapy; 28-day cycles with a half-cycle correction to drug costs over a lifetime horizon; 5 health states (stable disease, complete response, partial response, progressed disease, death). Comparators were combined as a basket weighted by confidential SpringWorks 2024 market research, and the committee assumed that chemotherapy was equivalent to nirogacestat for PFS.
- Utilities: De-Fi did not collect EQ-5D data. The company base case used soft-tissue sarcoma values from Shingler et al. 2013 (0.263 for progressed disease); the committee preferred EQ-5D values from Reichardt et al. 2012 (0.560 for progressed disease). The De-Fi QLQ-C30 data mapped to EQ-5D are confidential.
- Treatment duration: the committee assumed that 5% of people continue treatment into year 3 and that 10% of those in complete response, partial response, or stable disease are retreated at year 3 for up to 1 year. The NICE resource impact template assumes 1 year of treatment, the G-BA assumes one year (365 days), and Immunome states that patients may receive “~1.5–2 years of treatment”.
- Prices: nirogacestat U.S. WAC of $7,746.58 per package (01/05/2026), England list price of £15,189.04 per 56 pack of 150 mg tablets with a confidential discount, and German annual treatment cost of €260,760.82 per patient; sorafenib at $309/day at Medicare Part D rates (Johns et al. 2023).
- Patient numbers: SpringWorks estimates of 5,500 to 7,000 U.S. patients actively managed per year (market research) and approximately 11,000 receiving physician care (ICD-10 claims); Immunome's “10-11k Actively Managed Patients (US)”; 223 people eligible in England, derived from a soft-tissue sarcoma prevalence of 5.55 per 10,000 adults, 3% of which are desmoid tumors, an incidence of 4 per 1,000,000 adults, and 40% progressing; and approximately 350 to 630 patients in Germany.
- Other analyses: a SpringWorks-supported analysis of nirogacestat in DeFi (Malaviya et al. 2025) weighted health states with fixed utilities of 1.0, 0.5, and 0.5 over 20.6 months and reported a gain of 71.60 days versus placebo; it included no patient-reported utility data.
- No budget impact model of varegacestat was found: every heading of the budget impact model section of this report reads No evidence found.
NICE TA1199 recommendation of nirogacestat under a commercial arrangement
NICE TA1199 list price and confidential discount for nirogacestat
NICE TA1199 economic model structure: semi-Markov model with 28-day cycles, a lifetime horizon, and 5 health states
“The model contained 5 health states:” (opens the source at this quote in a new tab)
“stable disease” (opens the source at this quote in a new tab)
“complete response” (opens the source at this quote in a new tab)
“partial response” (opens the source at this quote in a new tab)
“progressed disease” (opens the source at this quote in a new tab)
NICE TA1199 comparators: best supportive care and chemotherapy, combined as a basket comparator
NICE TA1199 indirect comparison assumptions for objective response and progression-free survival
NICE TA1199 utility values: soft-tissue sarcoma proxies in the absence of EQ-5D data from De-Fi
NICE TA1199 treatment duration, discontinuation, and retreatment assumptions
NICE TA1199 modeling of ovarian dysfunction
NICE TA1199 acceptable ICER and confidential cost-effectiveness estimates
NICE TA1199 resource impact: eligible population and uptake of nirogacestat in England
NICE TA1199 resource impact: epidemiological assumptions for the eligible population
NICE TA1199 resource impact: treatment duration and capacity assumptions
G-BA added benefit rating and number of patients eligible for nirogacestat in Germany
G-BA annual treatment costs of nirogacestat in Germany
G-BA basis for treatment costs and patient numbers: pack price, consumption, and uncertainty
OGSIVEO wholesale acquisition cost, Connecticut disclosure dated January 2026
“Connecticut HB 6669” (opens the source at this quote in a new tab)
“82448-0100-14” (opens the source at this quote in a new tab)
“Oral Tablet 100 MG” (opens the source at this quote in a new tab)
“82448-0150-14” (opens the source at this quote in a new tab)
“Oral Tablet 150 MG” (opens the source at this quote in a new tab)
OGSIVEO wholesale acquisition cost at introduction, December 2023, superseded in January 2026
“82448-0050-18” (opens the source at this quote in a new tab)
“OGSIVEO (Nirogacestat) 50mg” (opens the source at this quote in a new tab)
“tablets, 180-ct bottle” (opens the source at this quote in a new tab)
“12/4/2023” (opens the source at this quote in a new tab)
“WAC AT INTRODUCTION” (opens the source at this quote in a new tab)
OGSIVEO recommended dosage, dose reductions, and package size
OGSIVEO U.S. net product revenue, 2023 and 2024
Ogsiveo net sales after the acquisition of SpringWorks, 2025
Ogsiveo net sales, first quarter 2026
Ogsiveo net sales, second quarter 2026
U.S. incidence and actively managed population estimated by SpringWorks Therapeutics
U.S. actively managed population, treatment duration, and sarcoma centers estimated by Immunome
Immunome expectation of gamma secretase inhibitor market share
Immunome expectations for payer coverage, pricing, and launch sites
Quality-adjusted time without symptoms or toxicity analysis of nirogacestat in DeFi, ISPOR Europe 2025
Cost per outcome of sorafenib at Medicare Part D prices
“Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.